Home › Funds › Bellevue Group AG › GILD
Bellevue Group AG position in GILD
GILEAD SCIENCES INC · Health Care
Bellevue Group AG reported holding 2,158,772 shares of GILD (GILEAD SCIENCES INC) in its Q2 2026 13F filing — a position valued at US$272.7M, representing 5.74% of its reported portfolio and ranking #4 among its reported holdings. Bellevue Group AG has disclosed GILD holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's GILD position evolved
Bellevue Group AG first disclosed a stake in GILD in Q3 2023 at 107,350 shares (US$8.0M). The position peaked in Q2 2026 at 2,158,772 shares, worth US$272.7M. Across 12 filings, Bellevue Group AG increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,158,772 shares valued at US$272.7M — an increase of 988,893 shares quarter over quarter.. Notable position changes include a 52% trim in Q4 2023 (shares fell 9% over the following quarter), a 2118% increase in Q1 2026 (shares fell 10% over the following quarter), a 85% increase in Q2 2026 (shares rose 18% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 107.35K | $8.04M | New |
| Q4 2023 | 51.30K | $4.16M | Reduce |
| Q1 2024 | 33.30K | $2.44M | Reduce |
| Q2 2024 | 38.93K | $2.67M | Add |
| Q3 2024 | 46.03K | $3.86M | Add |
| Q4 2024 | 48.43K | $4.47M | Add |
| Q1 2025 | 55.02K | $6.17M | Add |
| Q2 2025 | 51.42K | $5.70M | Reduce |
| Q3 2025 | 49.89K | $5.54M | Reduce |
| Q4 2025 | 52.75K | $6.47M | Add |
| Q1 2026 | 1.17M | $163.05M | Add |
| Q2 2026 | 2.16M | $272.74M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GILD and 13F data
GILD (GILEAD SCIENCES INC) is a Health Care company. 35 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.45B), Capital World Investors (US$5.18B), Capital World Investors (US$5.18B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GILD
- Fidelity Management & Research (FMR) 66.87M sh · $8.45B · Q2 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- Invesco Ltd 39.82M sh · $5.03B · Q2 2026
- PRICE T ROWE ASSOCIATES INC /MD/ 30.00M sh · $3.79B · Q2 2026
- Dodge & Cox 23.68M sh · $2.99B · Q2 2026
- DODGE & COX 23.68M sh · $2.99B · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held GILD?
Bellevue Group AG has disclosed GILD holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in GILD?
As of Q2 2026, Bellevue Group AG holds 2.16M shares of GILD (GILEAD SCIENCES INC), valued at $272.74M, representing 5.74% of its reported portfolio and ranking #4.
Has Bellevue Group AG been buying or selling GILD?
In the latest 13F filing (Q2 2026), Bellevue Group AG increased its position in GILD. The position peaked in Q2 2026 at 2.16M shares.
Which other funds hold GILD?
Other major institutional holders of GILD include Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.